ClassID:

97219

C07K16/4216 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig

Sub-classes:
Recent Application in this class:
#1
20250188193
2025-06-12

GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE

#2
20240150494
2024-05-09

GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE

#3
20220073648
2022-03-10

INFLUENZA VACCINES AND METHODS OF USE THEREOF

#4
20170283484
2017-10-05

Anti-hepatitis C antibodies and antigen binding fragments thereof

#5
20170198061
2017-07-13

INFLUENZA VACCINES AND METHODS OF USE THEREOF

#6
20170073431
2017-03-16

Humanized monoclonal antibodies and methods of use

#7
20160333055
2016-11-17

HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies

#8
20160200801
2016-07-14

Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes

#9
20160060325
2016-03-03

Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes

#10
20160002355
2016-01-07

IDIOTYPIC ANTIBODIES AND USES THEREOF

#11
20140037619
2014-02-06

HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies

#12
20130266973
2013-10-10

Idiotypic antibodies and uses thereof

#13
20130243749
2013-09-19

Humanized monoclonal antibodies and methods of use

#14
20120183533
2012-07-19

MIMOTOPES OF HIV ENV

#15
20110014187
2011-01-20

Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes

#16
20100310586
2010-12-09

Idiotypic vaccine

#17
20100247522
2010-09-30

Neutralization of HCV

#18
20080152586
2008-06-26

HIGH AVIDITY POLYVALENT AND POLYSPECIFIC REAGENTS

#19
20080075729
2008-03-27

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

#20
20060073166
2006-04-06

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

#21
17360489
2022-05-03

Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection